(Q37862259)

24 August 2017

1 reference

title

Pazopanib for the treatment of renal cancer (English)

1 reference

24 August 2017

main subject

pazopanib hydrochloride

1 reference

ChEBI release 2020-05-28

Mhd Yaser Al-Marrawi

1

1 reference

24 August 2017

Brian Rini

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

7 April 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

1171-1189

1 reference

24 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

The genetic basis of cancer of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Therapeutic potential of manipulating VEGF splice isoforms in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

The role of VEGF receptors in angiogenesis; complex partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Pazopanib: therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571206

10.1517/14656566.2011.571206

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference